Cell, Gene Therapy A No Entry Zone? EU Group Seeks Clarification Over China Regs
Should Be 'Unified And Consistent'
Executive Summary
China’s Negative List for Foreign Investment explicitly bars “investment and application in human stem cells, genetic diagnosis, and treatment technologies.” But whether that applies to foreign pharma firms developing such modalities in the country remains unclear.
You may also be interested in...
New China Foreign Investment Policies Include Biopharma Steps
Amid multinationals' accelerating de-risking and divestment moves in China, the country’s State Council has issued revised policies in the biologics manufacturing and gene therapy area, in a bid to attract foreign investment to the sector. But timely and consistent implementation will be key, an EU trade group says.
'Constantly Being Chased': Cutting-Edge Gene Therapy Developers Moving Fast In China
Plagued by a scandal which gained global attention a few years go, the gene therapy sector has recovered and is now thriving in China. But a drive for innovation, combined with ready cash for aspiring start-ups, may not translate into leaps and bounds in the field due to challenges unique to these latest treatments, including manufacturing, durability and coverage.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.